New study identifies brain circuit key to reducing cocaine-seeking behavior

Unlocking New Avenues for Treatment New advancements in neuroscience are offering promising strategies to combat cocaine use disorder, a challenging addictions spectrum often resistant to treatment. A pivotal study from Science Advances, led by experts at Penn Nursing, unearths a neural circuit that could significantly impact cravings and reduce relapse rates. The Role of Glucagon-like … Read more

San Antonio doctor addresses concerns over GLP-1 medications

GLP-1 Medications: The Rising Stars in Weight Management The popularity of GLP-1 medications like Ozempic, Mounjaro, and Wegovy is surging due to their effective role in weight management, even beyond their initial diabetic applications. Understanding their mechanism and potential future trends can shed light on the evolving landscape of healthcare and wellness solutions. The Science … Read more

Eye Doctors Are Finding New Links Between Ozempic and Vision Problems

The Growing Concerns Around GLP-1 Drugs and Eye Health Recent discussions in the medical community have raised concerns about the potential link between GLP-1 drugs like Ozempic and eye health. A series of studies, including a recent one from the University of Utah Health, highlight cases where individuals developing eye conditions after starting medications like … Read more

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

Expanding Horizons: Ozempic’s New FDA Approval Signals a Breakthrough for CKD Patients The U.S. Food and Drug Administration’s recent approval of Ozempic to mitigate risks associated with chronic kidney disease (CKD) in type 2 diabetes patients marks a significant development. This decision by Novo Nordisk underscores the growing intersection of diabetes management and kidney health. … Read more

GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity

The Evolving Role of GLP1RA in Diabetes Management and Mental Health As the use of GLP1RA—glucagon-like peptide 1 receptor agonists—grows in managing type 2 diabetes and obesity, there is increasing interest in their behavioral side effects. Recent research published in Diabetes, Obesity and Metabolism offers an in-depth look at these potential side effects and offers … Read more

Digbi Health Expands its Multi-Condition Care Platform to

The Future of Personalized Obesity Management PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) – Digbi Health’s cutting-edge precision biology-based approach is revolutionizing how obesity is managed. By introducing enhancements to their flagship GLP-Compass test, they’re setting new benchmarks in personalized healthcare. This innovative solution not only tailors treatment but also uses a data-driven methodology … Read more